pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-4-505-513pulmo-752Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYМесто фиксированной комбинации бронходилататоров длительного действия тиотропий / олодатерол в стартовой терапии хронической обструктивной болезни легких. Заключение Совета экспертов Российского респираторного обществаA role of long-acting bronchodilator tiotropium / olodaterol fixed combination as the first-line therapy of chronic obstructive pulmonary disease. A Consensus of Expert Board of Russian Respiratory SocietyАвдеевС. Н.AvdeevS. N.АйсановЗ. Р.AisanovZ. R.БелевскийА. С.BelevskiyA. S.ЗыковК. А.ZykovK. A.ЛещенкоИ. В.LeshchenkoI. V.ОвчаренкоС. И.OvcharenkoS. I.ШмелевЕ. И.ShmelevE. I.АрхиповВ. В.ArkhipovV. V.ГорблянскийЮ. Ю.GorblyanskiyYu. Yu.ЕмельяновА. В.Emel'yanovA. V.ИгнатоваГ. Л.IgnatovaG. L.КазанцевВ. А.KazantsevV. A.КаролиН. А.KaroliN. A.КолбасниковС. В.KolbasnikovS. V.КуделяЛ. М.KudelyaL. M.КузубоваН. А.KuzubovaN. A.СинопальниковА. И.Sinopal'nikovA. I.СтепанянИ. Э.StepanyanI. E.ТрофименкоИ. Н.TrofimenkoI. N.ФассаховР. С.FassakhovR. S.ХамитовР. Ф.KhamitovR. F.ШапороваН. Л.ShaporovaN. L.201618102016264505513Copyright © Авдеев С.Н., Айсанов З.Р., Белевский А.С., Зыков К.А., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Архипов В.В., Горблянский Ю.Ю., Емельянов А.В., Игнатова Г.Л., Казанцев В.А., Кароли Н.А., Колбасников С.В., Куделя Л.М., Кузубова Н.А., Синопальников А.И., Степанян И.Э., Трофименко И.Н., Фассахов Р.С., Хамитов Р.Ф., Шапорова Н.Л., 20162016Авдеев С.Н., Айсанов З.Р., Белевский А.С., Зыков К.А., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Архипов В.В., Горблянский Ю.Ю., Емельянов А.В., Игнатова Г.Л., Казанцев В.А., Кароли Н.А., Колбасников С.В., Куделя Л.М., Кузубова Н.А., Синопальников А.И., Степанян И.Э., Трофименко И.Н., Фассахов Р.С., Хамитов Р.Ф., Шапорова Н.Л.Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Zykov K.A., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I., Arkhipov V.V., Gorblyanskiy Y.Y., Emel'yanov A.V., Ignatova G.L., Kazantsev V.A., Karoli N.A., Kolbasnikov S.V., Kudelya L.M., Kuzubova N.A., Sinopal'nikov A.I., Stepanyan I.E., Trofimenko I.N., Fassakhov R.S., Khamitov R.F., Shaporova N.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/752

.

.

ReferencesGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for di-agnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2016. www.goldcopd.orgGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for di-agnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2016. www.goldcopd.orgMiravitlles M., Worth H., Soler Cataluña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122–127.Miravitlles M., Worth H., Soler Cataluña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122–127.Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstruc-tive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 976–981.Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstruc-tive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 976–981.Nishimura К., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1440.Nishimura К., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1440.Troosters T., Sciurba F., Battaglia S. et al. Physical inactivity in patients with COPD, a controlled multicenter pilot-study. Respir. Med. 2010; 104: 1005−1011.Troosters T., Sciurba F., Battaglia S. et al. Physical inactivity in patients with COPD, a controlled multicenter pilot-study. Respir. Med. 2010; 104: 1005−1011.Donaire-Gonzalez D., Gimeno-Santos E., Balcells E. Physical activity in COPD patients: patterns and bouts. Eur. Respir. J. 2013; 42: 993–1002.Donaire-Gonzalez D., Gimeno-Santos E., Balcells E. Physical activity in COPD patients: patterns and bouts. Eur. Respir. J. 2013; 42: 993–1002.Waschki B., Kirsten A., Holz O. et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140: 331–342.Waschki B., Kirsten A., Holz O. et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140: 331–342.Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15-61.Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Pul'monologiya. 2014; 3: 15–61 (in Russian).Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 8 (361): 449–456.Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 8 (361): 449–456.Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomized, double blind placebo con-trolled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE-trial. Br. Med. J. 2000; 320 (7245): 1297–1303.Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomized, double blind placebo con-trolled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE-trial. Br. Med. J. 2000; 320 (7245): 1297–1303.Soriano J.B., Sin D.D., Zhang X. et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007; 131 (3): 682–689.Soriano J.B., Sin D.D., Zhang X. et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007; 131 (3): 682–689.Wedzicha J.A., Calverley P., Seemunqal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19–26.Wedzicha J.A., Calverley P., Seemunqal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19–26.Wedzicha J.A., Banerji D., Chapman K. R. et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD.N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Wedzicha J.A., Banerji D., Chapman K. R. et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD.N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (11): 1079–1084.Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (11): 1079–1084.Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch. Int. Med. 2009; 169: 219–229.Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch. Int. Med. 2009; 169: 219–229.Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 295–304.Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 295–304.Lapi F., Kezouh A., Suissa S., Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur. Respir. J. 2013; 42: 79–86.Lapi F., Kezouh A., Suissa S., Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur. Respir. J. 2013; 42: 79–86.Tashkin D.P. et al. UPLIFT study investigators. N. Engl. J. Med. 2008; 359: 1543–1554.Tashkin D.P. et al. UPLIFT study investigators. N. Engl. J. Med. 2008; 359: 1543–1554.Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9: 963–974.Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9: 963–974.Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 1-я). Пульмонология. 2016; 2: 155.Chronic Obstructive Pulmonary Disease: Preventing Acute Exacerbations. Clinical Guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (part 1). Pul'monologiya. 2016; 2: 155 (in Russian).Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 2-я). Пульмонология. 2016; 3: 170.Chronic Obstructive Pulmonary Disease: Preventing Acute Exacerbations. Clinical Guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (part 2). Pul'monologiya. 2016; 3: 170 (in Russian).Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecied subgroup analysis of a randomised controlled trial. Lancet. 2009; 374: 1171–1178.Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecied subgroup analysis of a randomised controlled trial. Lancet. 2009; 374: 1171–1178.Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD: The TIOSPIR Trial. N. Engl. J. Med. 2013; 369 (10): 1491–501.Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD: The TIOSPIR Trial. N. Engl. J. Med. 2013; 369 (10): 1491–501.Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.Bateman E.D., Tashkin D., Siafakas N. et al. A one year trial of tiotropium Respimat® plus usual therapy in COPD patients. Resp. Med. 2010; 104: 1460–1472.Bateman E.D., Tashkin D., Siafakas N. et al. A one year trial of tiotropium Respimat® plus usual therapy in COPD patients. Resp. Med. 2010; 104: 1460–1472.Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533.Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533.Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.Beeh K.-M., Westerman J., Kirsten A.-M. et al. The 24-h lung function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53–59.Beeh K.-M., Westerman J., Kirsten A.-M. et al. The 24-h lung function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53–59.Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45: 969–979.Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45: 969–979.Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.Profita M., Bonanno A., Montalbano A.M. et al. β2-Long-acting and anticholinergic drugs control TGF β1-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 2012; 1822: 1079–1089.Profita M., Bonanno A., Montalbano A.M. et al. β2-Long-acting and anticholinergic drugs control TGF β1-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 2012; 1822: 1079–1089.Авдеев С.Н. Новые возможности использования тиотропия бромида с помощью аэрозольного устройства доставки – ингалятора Респимат. Пульмонология. 2013; 5: 70–80.Avdeev S.N. New abilities of treatment with tiotropium bromide delivered via Respimat aerosol device. Pul'monologiya. 2013; 5: 70–80 (in Russian).Martinez F.J., Abrahams R., Ferguson G.T. et al. Effects of symptom severity at baseline on lung-function and SGRQ responses in the OTEMTO® studies. Am. J. Respir. Crit. Care Med. 2016; 193: A6787.Martinez F.J., Abrahams R., Ferguson G.T. et al. Effects of symptom severity at baseline on lung-function and SGRQ responses in the OTEMTO® studies. Am. J. Respir. Crit. Care Med. 2016; 193: A6787.Buhl R., McGarvey L., Korn S. et al. Benefits of tiotropium + olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. Am. J. Respir. Crit Care Med. 2016; 193: A6779.Buhl R., McGarvey L., Korn S. et al. Benefits of tiotropium + olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. Am. J. Respir. Crit Care Med. 2016; 193: A6779.Singh D., Gaga M., Schmidt O. et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir. Res. 2016; 17: 73.Singh D., Gaga M., Schmidt O. et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir. Res. 2016; 17: 73.Чазова И. Е., Чучалин А. Г., Зыков К. А., Ратова Л. Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 10 (1): 5–34.Chazova I. E., Chuchalin A. G., Zykov K. A., Ratova L. G. Diagnosis and Treatment of Patients with Hypertension and Chronic Obstructive Pulmonary Disease (Guidelines of Russian Medical Society on Hypertension and Russian Respiratory Society). Sistemnye gipertenzii. 2013; 10 (1): 5–34 (in Russian).Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 948–955.Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 948–955.Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–501.Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–501.Jenkins C.R. More than just reassurance on tiotropium safety. N. Engl. J. Med. 2013; 369 (16): 1555–1556.Jenkins C.R. More than just reassurance on tiotropium safety. N. Engl. J. Med. 2013; 369 (16): 1555–1556.Cave A.C., Hurst M.M. The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol. Ther. 2011; 130: 114–143.Cave A.C., Hurst M.M. The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol. Ther. 2011; 130: 114–143.Lahousse L., Verhamme K., Stricker B., Brusselle G. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016; 4: 149–164.Lahousse L., Verhamme K., Stricker B., Brusselle G. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016; 4: 149–164.

The authors declare that there are no conflicts of interest present.